HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract

International Journal of Gastrointestinal Cancer

Volumn 35, Issue 1, 2005, Pages 15-23

  Hansel, Donna E ^a   Rahman, Ayman ^a   Wilentz, Robb E ^a   Shih, Ie Ming ^a   McMaster, Michael T ^b   Yeo, Charles J ^a   Maitra, Anriban ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ampullary cancer; Biliary cancer; Colon; Colorectal cancer; Gallbladder; Immune; Pancreas; Pancreatic cancer; Tolerance

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HLA G ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOMA; ANTIBODY LABELING; ANTIGEN EXPRESSION; ARTICLE; BILE DUCT CANCER; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER STAGING; CELL LABELING; CELL TYPE; COLON; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; PANCREAS CARCINOMA; PRECANCER; PRIORITY JOURNAL; T LYMPHOCYTE; TUBULOVILLOUS ADENOMA; TUMOR ESCAPE; UPREGULATION; VATER PAPILLA CARCINOMA;

EID: 16244414325     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1385/ijgc:35:1:015     Document Type: Article

References (23)

1. O'Callaghan CA, Bell JI. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 1998;163:129-138.
2. Marin R, Ruiz-Cabello F, Pedrinaci S, et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003;54:767-775.
3. Carosella ED, Moreau P, Aractingi S, Rouas-Freiss N. HLA-G: a shield against inflammatory aggression. Trends Immunol 2001;22:553-555.
4. Amiot L, Onno M, Drenou B, et al. Distribution of HLA-G alternative mRNAs including soluble forms in normal lymphocytes and in lymphoid cell-derived leukemia. Eur J Immunogenet 1996;23:311-320.
5. Onno M, Guillaudeux T, Amiot L, et al. The HLA-G gene is expressed at a low mRNA level in different human cells and tissues. Hum Immunol 1994;41:79-86.
6. Singer G, Kurman RJ, McMaster MT, Shih Ie M. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 2002;26:914-920.
7. Urosevic M, Kurrer MO, Kamarashev J, et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 2001;159:817-824.
8. Pangault C, Amiot L, Caulet-Maugendre S, et al. HLA-G protein expression is not induced during malignant transformation. Tissue Antigens 1999;53:335-346.
9. Seliger B, Abken H, Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003;24:82-87.
10. Urosevic M, Willers J, Mueller B, et al. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 2002;99:609-617.
11. Wiendl H, Mitsdoerffer M, Hofmeister V, et al. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 2002;168:4772-4780.
12. Paul P, Cabestre FA, Ibrahim EC, et al. Identification of HLA-G7 as a new splice variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6, and -G7 transcripts in human transfected cells. Hum Immunol 2000;61:1138-1149.
13. Fournel S, Aguerre-Girr M, Huc X, et al. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol 2000;164:6100-6104.
14. Riteau B, Rouas-Freiss N, Menier C, et al. HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 2001;166:5018-5026.
15. Riteau B, Menier C, Khalil-Daher I, et al. HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 1999;43:203-211.
16. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+)T-lymphocytes. J Reprod Immunol 2000;48:17-26.
17. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol, 2002;161:1541-1547.
18. Carosella ED, Paul P, Moreau P, Rouas-Freiss N. HLA-G and HLA-E: fundamental and pathophysiological aspects. Immunol Today 2000;21:532-534.
19. Contini P, Ghio M, Poggi A, et al. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003;33:125-134.
20. Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, et al. A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 2001;33:2355-2359.
21. Paul P, Rouas-Freiss N, Khalil-Daher I, et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998;95:4510-4515.
22. Singer G, Rebmann V, Chen Y-C, et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003;9:4460-4464.
23. Fukushima Y, Oshika Y, Nakamura M, et al. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med 1998;2:349-351.